Platelet-rich Plasma Intradermal Injection Combined With 308 nm Excimer Light for Treating Stable Acral Vitiligo

Launched by YIJIAN ZHU · Apr 27, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for adults with stable acral vitiligo, a condition that causes white patches on the skin, particularly on the hands and fingers. The researchers want to find out if using platelet-rich plasma (PRP) injections, combined with a specific type of light therapy called 308 nm excimer light, is more effective than using the light therapy alone. They will also look at how safe the PRP injections are for the participants.

To be eligible for the trial, participants need to have stable vitiligo for at least six months and have specific areas of white patches on their hands and fingers. They should not have received certain treatments in the past year and must voluntarily agree to participate. Those who join the study will receive monthly PRP injections along with light therapy sessions twice a week for six months. They will visit the clinic once a month for evaluations and keep a diary to track any symptoms or side effects they experience. This trial is currently recruiting participants, and it aims to provide valuable information about a potential new treatment option for vitiligo.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with non-segmental vitiligo stable for more than half a year;
• • At least 1 separate stable lesion on each of the dorsum of the right and left hands, proximal fingers, distal fingers and palms;
• • The area of white spots is less than 10 % of the total body surface area and more than 1 % of the total body surface area;
• • Those who have not received systemic treatment of vitiligo and phototherapy or related treatments within 1 month ≥ 1 year without significant efficacy;
• • Voluntary signing of informed consent.
• Exclusion Criteria:
• • Pregnant and lactating women;
• • Those who have used glucocorticoids or other immunosuppressants in the last 3 months;
• • Suffering from haematological disorders such as coagulation abnormalities and thrombocytopoietic disorders;
• • Those who are allergic to ultraviolet light and photosensitive treatment;
• • Scar constitution;
• • Those with current or previous history of skin cancer or family history of skin cancer;
• • Those with infectious diseases such as HIV, syphilis, hepatitis B or C;
• • Those with other serious systemic diseases;
• • Patients who, in the judgement of the investigator, are not suitable for inclusion in this trial.